Open an account

Quince Therapeutics

IRLA · NASDAQ

$33.08+$0.25 (+0.76%)TodayMarket closed ·
Prev close $32.83

About IRLA

Quince Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 38 full-time employees. The company went IPO on 2019-05-09. Quince Therapeutics, Inc. is a late-stage biotechnology company. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Employees
38
Headquarters
South San Francisco, California
Listed
May 9, 2019
Sector
Health Care
Industry
Biotechnology
Website
quincetx.com

IRLA key statistics

Market cap
33.64M
Price-earnings ratio
0.23
Dividend yield
—
Average volume
66.30K
Volume
89.80K
Open price
$31.61
High today
$33.21
Low today
$27.40
52 Week high
$909.98
52 Week low
$15.10

Quince Therapeutics (IRLA) at a glance

As of Oct 23, 2026, Quince Therapeutics (IRLA) shares are priced at $33.08, giving the company a market cap of 33.64M and a price-to-earnings ratio of 0.23.

Today the stock has traded between $27.40 and $33.21. The current price is 20.8% above the day's low and 0.4% below its high.

Volume so far is 89.80K shares, above the average of 66.30K shares a day.

Over the past year Quince Therapeutics has ranged from $15.10 to $909.98, and now sits 2% of the way up that range.

Quince Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$12.31 per share against an estimate of -$18.24.

IRLA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 73.1% on average.

  1. Q3 FY24: reported -$26.00 per share against an estimate of -$42.84
  2. Q4 FY24: reported -$56.00 per share against an estimate of -$35.70
  3. Q1 FY25: reported -$68.00 per share against an estimate of -$46.41
  4. Q2 FY25: reported -$46.00 per share against an estimate of -$51.34
  5. Q3 FY25: reported -$50.00 per share against an estimate of -$44.15
  6. Q4 FY25: reported -$142.00 per share against an estimate of -$38.52
  7. Q1 FY26: reported $57.60 per share against an estimate of -$52.22
  8. Q2 FY26: reported -$12.31 per share against an estimate of -$18.24

IRLA news

  • Press releaseGlobe Newswire

    IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

Similar companies

Companies in the same industry as Quince Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.